6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Published on
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_______________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For
the
month of March, 2006.
Commission
File Number ________________
Novogen
Limited
(Translation
of registrant’s name into English)
140
Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F
x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7):
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form
6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes o No
o
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
82-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
Novogen
Limited
(Registrant)
/s/
Ron Erratt
Ronald
Lea Erratt
Company
Secretary
Date
29 March, 2006
ASX
& MEDIA RELEASE
29
MARCH 2006
APPOINTMENT
OF NEW GOVERNOR CREATES BOARD VACANCY AT MARSHALL EDWARDS,
INC.
Novogen
Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has just made the
following announcement:
Sydney:
March 29, 2006 - Following the appointment of current MEI Director Professor
David de Kretser AO as the next Governor of the Australian state of Victoria,
a
vacancy has been created on the board of Marshall Edwards Inc. which is to
be
filled by Professor Bryan Williams.
Professor
Williams is the Director of the Monash Institute of Medical Research in
Melbourne, Australia succeeding Professor de Kretser. Prior to his appointments
to the Monash Institute, New Zealand born Professor Williams enjoyed a
distinguished international career as a cancer researcher in the basic and
preclinical area.
Positions
held in recent years included a professorial chair at Case Western Reserve
University, Cleveland, Ohio and adjunct professorships at Cleveland State
University, and at Kent State University also both in Ohio, USA. Immediately
before coming to Melbourne, Professor Williams was Chairman of the Department
of
Cancer Biology, Lerner Research Institute, The Cleveland Clinic Foundation,
Cleveland, Ohio, one of the leading cancer clinics in the US.
Welcoming
Professor Williams to the board, Marshall Edwards’ Chief Executive Officer, Mr
Christopher Naughton, said his particular expertise and experience would
assist
with progressing the development of phenoxodiol, Marshall Edwards’ lead
anti-cancer compound.
Professor
Williams joins the MEI board of directors which includes Professor Graham
Kelly
(Chairman), Mr Naughton (CEO), Professor Paul Nestel AO, and Messrs Philip
Johnston and Stephen Breckenridge.
Directors
of Marshall Edwards congratulated Professor de Kretser on his appointment
as
Governor and wished him well in his position which they said was public
recognition of his judgment, his illustrious career, his active and ongoing
management and involvement in medical research and his advocacy across a
broad
range of biotechnology.
Incorporated
in the US State of Delaware, Marshall Edwards Inc. is 87 percent owned by
ASX
and NASDAQ listed pharmaceutical company, Novogen Limited from which it licences
phenoxodiol, and its shares are traded in the US on NASDAQ (Code: MSHL).
More
information on phenoxodiol and on the company can be found at www.marshalledwardsInc
com
and
www.novogen.com
ISSUED
FOR : NOVOGEN
LIMITED
LISTINGS : ASX
(CODE NRT), NASDAQ (CODE NVGN).
FOR
FURTHER
INFORMATION : CHRISTOPHER
NAUGHTON, MANAGING DIRECTOR, NOVOGEN LIMITED
TEL
(02) 9878 0088 http://www.novogen.com
ISSUED
BY : WESTBROOK
COMMUNICATIONS
CONTACT:
DAVID REID TEL (02) 9231 0922 OR 0417 217 157